Bacteriophages are naturally occurring viruses that selectively infect and destroy bacteria. Unlike broad-spectrum antibiotics, phages can be precisely matched to specific bacterial pathogens, enabling targeted treatment while minimising off-target effects.

Xenova Biosciences develops rigorously characterised, lytic bacteriophage cocktails designed for clinical use. Our approach combines modern microbiology, genomic characterisation, and pharmaceutical development principles to create safe, scalable phage-based therapeutics.

Our development strategy emphasises:

• Strictly lytic phage selection

• Comprehensive genomic characterisation

• Robust manufacturing and quality control

• Regulatory-aligned CMC development